Search This Blog

1

Labels

Cancer (150) Breast (38) Study (38) Health (32) Patients (31) Treatment (27) Could (23) Therapy (19) Research (17) Against (12) Blood (11) Disease (11) linked (11) Diabetes (10) Early (10) Prevent (10) Survival (10) Treatments (7) higher (7) surgery (7) Might (6) Prostate (6) Tumors (6) During (5) Effects (5) Growth (5) Chemotherapy (4) Drinking (4) Prevention (4) Obama (3) Obesity (3) Without (3) associated (3) Experts (2) Important (2) Infection (2) About (1) Analysis (1) Causes (1) Eliminate (1) stroke (1)

AD

Showing posts with label should. Show all posts
Showing posts with label should. Show all posts

Saturday, September 28, 2013

Europe should shift focus to bowel cancer screening to save lives: scientists

By Kate Kelland

AMSTERDAM (Reuters) - European governments should divert funds to routine bowel cancer tests from less effective breast and prostate screening programs, scientists said on Saturday, presenting what they called "irrefutable" evidence that bowel screening saves lives.

Many governments devote significant funds to breast cancer screening, but studies in recent years have found that routine breast mammograms can also lead to so-called "over-diagnosis" when tests pick up tumors that would not have caused a problem.

The risk of over-diagnosis in bowel cancer screening is very low, while gains in terms of reducing deaths are large - making routine testing cost-effective, Philippe Autier, a professor at France's International Prevention Research Institute, told the European Cancer Conference in Amsterdam.

"There is now an irrefutable case for devoting some of the resources from breast and prostate cancer screening to the early detection of colorectal (bowel) cancer," he said.

A large European study published last year found that breast screening programs over-diagnose about four cases for every 1,000 women aged between 50 and 69 who are screened.

Colorectal cancer kills more than 600,000 people a year worldwide, according to the World Health Organization. In Europe some 400,000 people are diagnosed with the disease each year.

Results of a study conducted by Autier using data from 11 European countries between 1989 and 2010 showed that the greater the proportions of men and women routinely screened for bowel cancer, the greater the reductions in death rates.

In Austria, for example, where 61 percent of those studied reported having had colorectal screening tests, deaths from this form of cancer dropped by 39 percent for men and 47 percent for women over the decade.

Meanwhile in Greece, where only 8 percent of males had had bowel cancer screening, death rates rose by 30 percent for men.

In the light of the results, Cornelis van de Velde, an oncologist at Leiden University Medical Centre in the Netherlands and president of the European Cancer Organisation, said it was "very disappointing" there are such wide differences in European governments' approaches to colorectal screening.

"People over 50 should be informed of the availability of the test, and pressure should be put on national health services to put more effort into organizing screening programs," he told the conference.

Screening for early signs of bowel cancer involves either a faecal occult blood test, which checks a sample of feces for hidden blood, or endoscopy, where a tiny camera is introduced into the large bowel to look for the polyps that can be a precursor of cancer.

In some European countries, such as France, Germany and Austria, many men and women over the age of 50 have regular colorectal screening examinations, while in others, such as The Netherlands and Britain, screening is much less common.

(Editing by Louise Ireland)


View the original article here

Sunday, July 1, 2012

All baby boomers should get hepatitis C test -CDC

AppId is over the quota
AppId is over the quota

(Reuters) - All baby boomers should be tested at least once for the liver-destroying hepatitis C virus, according to proposed guidelines from U.S. health officials released on Friday.

The often-undiagnosed virus is transmitted through contaminated blood. While infection rates have dropped dramatically since the early 1990s - due in part to the introduction of blood and organ screening - many older adults are still at risk, according to the U.S. Centers for Disease Control and Prevention, which released the draft guidelines.

According to the CDC, one in 30 baby boomers - the generation born from 1945 through 1965 - has been infected with hepatitis C, and most do not know it.

A one-time, cost-effective blood test would "identify hundreds of thousands of hidden infections," said Dr John Ward, director of CDC's division of viral hepatitis.

He likened the proposal to existing age-related guidelines on screening for diseases including breast cancer, cervical cancer and high cholesterol.

Hepatitis C causes serious liver diseases, including liver cancer - the fastest-rising cause of cancer-related deaths - and is the leading cause of liver transplants in the United States.

The CDC said it believes routine blood tests will address the largely preventable consequences of the disease, especially in light of newly available therapies that can cure around 75 percent of infections.

The field has attracted broad interest with two new hepatitis C drugs - Incivek from Vertex Pharmaceuticals Inc and Merck & Co's Victrelis - reaching the U.S. market in the past year.

Companies including Gilead Sciences Inc and Bristol-Myers Squibb Co aim to improve on those medicines with pills that do not need to be combined with injections of immune system boosters, which have side effects that can deter patients.

More than 15,000 Americans, most of them baby boomers, die each year from hepatitis C-related illness, such as cirrhosis and liver cancer.

Current U.S. guidelines call for testing only individuals with certain known risk factors for hepatitis C infection.

The CDC said it will accept public comment on the draft recommendations from May 22 to June 8.

Final recommendations will be issued later this year.

(Reporting By Deena Beasley in Los Angeles; editing by John Wallace and Matthew Lewis)